PET Detection of CCR2 in Human Atherosclerosis
ConditionCarotid Atherosclerosis
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-89
SponsorWashington University School of Medicine
About this trial
: Use of novel radio-pharmaceutical 64CUDOTA-ECL1i to evaluate arterial atherosclrosis
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)
DrugPatients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)
DrugPatients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
Treatment groups
100 Participants
are divided into 2 treatment groupsGroup A: Aim 1AExperimental treatment 1 intervention
Group B: Aim 1BExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Evaluation of 64CU-ECL1i , imaging characteristics
Injecting normal volunteers and patients who have blocked arteries with a single bolus injection. The dose of the injection is 8-10, and the above drug is measured in millicuries, which is a unit of radioactivity. the dose of millicuries will be 8-10 millicures
Time frame
1 or 2 daysSecondary outcomes
1
PET/MR camera, imaging performance
Utilizing the PET/MR camera using audiography, which can show the presence and size of the blockage
Time frame
1-2 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov